Smith & Nephew SNATS (NYSE:SNN) Upgraded by Wall Street Zen to Buy Rating

by · The Cerbat Gem

Wall Street Zen upgraded shares of Smith & Nephew SNATS (NYSE:SNN – Free Report) from a hold rating to a buy rating in a research report report published on Sunday morning,Wall Street Zen reports.

Other analysts have also issued reports about the stock. Barclays lowered shares of Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded Smith & Nephew SNATS from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, September 4th. BTIG Research initiated coverage on Smith & Nephew SNATS in a research note on Monday, August 31st. They set a “neutral” rating on the stock. The Goldman Sachs Group reiterated a “buy” rating on shares of Smith & Nephew SNATS in a report on Monday, May 25th. Finally, Morgan Stanley lowered Smith & Nephew SNATS from an “overweight” rating to an “equal weight” rating in a research note on Wednesday, September 2nd. One research analyst has rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $31.91.

Get Our Latest Stock Analysis on SNN

Smith & Nephew SNATS Trading Down 0.0%

Smith & Nephew SNATS stock opened at $27.50 on Friday. The firm has a 50-day moving average price of $29.94 and a 200-day moving average price of $31.13. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 2.14. Smith & Nephew SNATS has a 12-month low of $27.23 and a 12-month high of $38.44.

Smith & Nephew SNATS Announces Dividend

The business also recently disclosed a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be issued a dividend of $0.312 per share. The ex-dividend date is Friday, October 2nd. This represents a yield of 205.0%.

Institutional Investors Weigh In On Smith & Nephew SNATS

Large investors have recently added to or reduced their stakes in the stock. Equity Investment Corp boosted its holdings in shares of Smith & Nephew SNATS by 3.9% in the 4th quarter. Equity Investment Corp now owns 7,502 shares of the medical equipment provider’s stock valued at $246,000 after buying an additional 285 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of Smith & Nephew SNATS by 13.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,820 shares of the medical equipment provider’s stock worth $93,000 after buying an additional 334 shares during the last quarter. Cary Street Partners Financial LLC raised its stake in shares of Smith & Nephew SNATS by 1.8% during the 4th quarter. Cary Street Partners Financial LLC now owns 20,255 shares of the medical equipment provider’s stock worth $665,000 after acquiring an additional 365 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Smith & Nephew SNATS by 20.0% during the 1st quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock worth $74,000 after acquiring an additional 387 shares in the last quarter. Finally, Clearstead Trust LLC bought a new position in shares of Smith & Nephew SNATS during the 2nd quarter worth approximately $25,000. 25.64% of the stock is owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Company Profile

(Get Free Report)

Smith & Nephew plc is a global medical technology company headquartered in the United Kingdom. Founded in 1856 by Thomas James Smith in Hull, the company initially operated as a pharmacy business before expanding into healthcare products and medical devices.

The company develops and manufactures technologies used in orthopaedic reconstruction, sports medicine, and advanced wound management. Its products include joint replacement systems, trauma and extremities devices, arthroscopic equipment, surgical repair technologies, wound dressings, negative-pressure wound therapy systems, and other products designed to support tissue healing and surgical care.

Smith & Nephew serves hospitals, healthcare professionals, and patients in markets around the world.

Read More